The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro

Clinical Immunology

Volumn 127, Issue 3, 2008, Pages 330-339

  Blake, Stephen ^a,b   Hughes, Timothy P ^a,b   Mayrhofer, Graham ^a,b   Lyons, A Bruce ^a,b,c,d  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c FLINDERS MEDICAL CENTRE   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

Author keywords

Immune suppression; Leukemia; Signal transduction; T cells

Indexed keywords

7 AMINODACTINOMYCIN; ABELSON KINASE; CD3 ANTIGEN; CD4 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; CONCANAVALIN A; CYCLOSPORIN; CYTOKINE; DASATINIB; DIPEPTIDYL PEPTIDASE IV; IMATINIB; INTERLEUKIN 2 RECEPTOR ALPHA; LIPOCORTIN 5; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; T LYMPHOCYTE RECEPTOR;

ARTICLE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE FUNCTION; NORMAL HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELL PROLIFERATION; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; ONCOGENE PROTEINS V-ABL; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; T-LYMPHOCYTES; THIAZOLES;

EID: 45449102076     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.02.006     Document Type: Article

References (33)

1. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
2. Daley G.Q., Van Etten R.A., and Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247 (1990) 824-830
3. Lugo T.G., Pendergast A.M., Muller A.J., and Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247 (1990) 1079-1082
4. Hochhaus A., Kantarjian H.M., Baccarani M., Lipton J.H., Apperley J.F., Druker B.J., Facon T., Goldberg S.L., Cervantes F., Niederwieser D., Silver R.T., Stone R.M., Hughes T.P., Muller M.C., Ezzeddine R., Countouriotis A.M., and Shah N.P. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109 (2007) 2303-2309
5. Schittenhelm M.M., Shiraga S., Schroeder A., Corbin A.S., Griffith D., Lee F.Y., Bokemeyer C., Deininger M.W., Druker B.J., and Heinrich M.C. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 66 (2006) 473-481
6. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., Cortes J., O'Brien S., Nicaise C., Bleickardt E., Blackwood-Chirchir M.A., Iyer V., Chen T.T., Huang F., Decillis A.P., and Sawyers C.L. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354 (2006) 2531-2541
7. Song L., Morris M., Bagui T., Lee F.Y., Jove R., and Haura E.B. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 66 (2006) 5542-5548
8. Nam S., Kim D., Cheng J.Q., Zhang S., Lee J.H., Buettner R., Mirosevich J., Lee F.Y., and Jove R. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 65 (2005) 9185-9189
9. Parsons S.J., and Parsons J.T. Src family kinases, key regulators of signal transduction. Oncogene 23 (2004) 7906-7909
10. Molina T.J., Kishihara K., Siderovski D.P., van Ewijk W., Narendran A., Timms E., Wakeham A., Paige C.J., Hartmann K.U., Veillette A., et al. Profound block in thymocyte development in mice lacking p56lck. Nature 357 (1992) 161-164
11. Sugie K., Jeon M.S., and Grey H.M. Activation of naive CD4 T cells by anti-CD3 reveals an important role for Fyn in Lck-mediated signaling. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 14859-14864
12. Feshchenko E.A., Langdon W.Y., and Tsygankov A.Y. Fyn, Yes, and Syk phosphorylation sites in c-Cbl map to the same tyrosine residues that become phosphorylated in activated T cells. J. Biol. Chem. 273 (1998) 8323-8331
13. Lee F.Y., Lombardo L., Camuso A., Castaneda S., Fager K., Flefleh C., Inigo I., Johnson K., Kan D., Luo R., McGlinchey K., Pang S., Peterson R., Wen M.-L., Wild R., Fairchild C., Wong T., Borzilleri R., and Kramer R. BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo. AACR Meet. Abstr. 2005 (2005) 159-b
14. Carter T.A., Wodicka L.M., Shah N.P., Velasco A.M., Fabian M.A., Treiber D.K., Milanov Z.V., Atteridge C.E., Biggs III W.H., Edeen P.T., Floyd M., Ford J.M., Grotzfeld R.M., Herrgard S., Insko D.E., Mehta S.A., Patel H.K., Pao W., Sawyers C.L., Varmus H., Zarrinkar P.P., and Lockhart D.J. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11011-11016
15. Das J., Chen P., Norris D., Padmanabha R., Lin J., Moquin R.V., Shen Z., Cook L.S., Doweyko A.M., Pitt S., Pang S., Shen D.R., Fang Q., deFex H.F., McIntyre K.W., Shuster D.J., Gillooly K.M., Behnia K., Schieven G.L., Wityak J., and Barrish J.C. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2- methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J. Med. Chem. 49 (2006) 6819-6832
16. Fabian M.A., Biggs W.H., Treiber D.K., Atteridge C.E., Azimioara M.D., Benedetti M.G., Carter T.A., Ciceri P., Edeen P.T., Floyd M., Ford J.M., Galvin M., Gerlach J.L., Grotzfeld R.M., Herrgard S., Insko D.E., Insko M.A., Lai A.G., Lelias J.M., Mehta S.A., Milanov Z.V., Velasco A.M., Wodicka L.M., Patel H.K., Zarrinkar P.P., and Lockhart D.J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23 (2005) 329-336
17. Seggewiss R., Lore K., Greiner E., Magnusson M.K., Price D.A., Douek D.C., Dunbar C.E., and Wiestner A. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105 (2005) 2473-2479
18. Cwynarski K., Laylor R., Macchiarulo E., Goldman J., Lombardi G., Melo J.V., and Dazzi F. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 18 (2004) 1332-1339
19. Dietz A.B., Souan L., Knutson G.J., Bulur P.A., Litzow M.R., and Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104 (2004) 1094-1099
20. Gao H., Lee B.N., Talpaz M., Donato N.J., Cortes J.E., Kantarjian H.M., and Reuben J.M. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia 19 (2005) 1905-1911
21. Mattiuzzi G.N., Cortes J.E., Talpaz M., Reuben J., Rios M.B., Shan J., Kontoyiannis D., Giles F.J., Raad I., Verstovsek S., Ferrajoli A., and Kantarjian H.M. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin. Cancer Res. 9 (2003) 976-980
22. Steegmann J.L., Moreno G., Alaez C., Osorio S., Granda A., de la Camara R., Arranz E., Reino F.G., Salvanes F.R., Fernandez-Ranada J.M., and Munoz C. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica 88 (2003) 762-768
23. Lyons A.B., and Parish C.R. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171 (1994) 131-137
24. Kahan B.D. Cyclosporine. N. Engl. J. Med. 321 (1989) 1725-1738
25. Bickel M., Tsuda H., Amstad P., Evequoz V., Mergenhagen S.E., Wahl S.M., and Pluznik D.H. Differential regulation of colony-stimulating factors and interleukin 2 production by cyclosporin A. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 3274-3277
26. Granelli-Piperno A., Inaba K., and Steinman R.M. Stimulation of lymphokine release from T lymphoblasts. Requirement for mRNA synthesis and inhibition by cyclosporin A. J. Exp. Med. 160 (1984) 1792-1802
27. Zamoyska R., Basson A., Filby A., Legname G., Lovatt M., and Seddon B. The influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival and activation. Immunol. Rev. 191 (2003) 107-118
28. Seddon B., Legname G., Tomlinson P., and Zamoyska R. Long-term survival but impaired homeostatic proliferation of naive T cells in the absence of p56lck. Science 290 (2000) 127-131
29. Rix U., Hantschel O., Durnberger G., Remsing Rix L.L., Planyavsky M., Fernbach N.V., Kaupe I., Bennett K.L., Valent P., Colinge J., Kocher T., and Superti-Furga G. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib reveal novel kinase and non-kinase targets. Blood 110 (2007) 4055-4063
30. Copland M., Hamilton A., Elrick L.J., Baird J.W., Allan E.K., Jordanides N., Barow M., Mountford J.C., and Holyoake T.L. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107 (2006) 4532-4539
31. Sawyers C.L., Shah N.P., Kantarjian H.M., Donato N., Nicoll J., Bai S.A., Huang F., Clark E., DeCillis A.P., and Talpaz M. Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354825: results from a phase I dose escalation study. ASH Ann. Meet. Abstr. 104 (2004) 1
32. Fruman D.A., Klee C.B., Bierer B.E., and Burakoff S.J. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 3686-3690
33. Clipstone N.A., and Crabtree G.R. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357 (1992) 695-697